Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT07582237
Active, not recruiting Observational

Long-Term Follow-up Study of FURESTEM-AD in Patients With Atopic Dermatitis(K0106)

NCT07582237 · tracked via the Priya Life Science South Korea tracker
Sponsor
Kang Stem Biotech Co., Ltd
Phase
Observational
Started
2021-10-05
Last updated
2026-05-12

Condition(s) studied

Dermatitis, Atopic

Study summary

Long-Term Follow-up Study of Subjects With Moderate to Severe Chronic Atopic Dermatitis Who Had Administered FURESTEM-AD Inj. in K0106 Study

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Those who participated in the K0106 clinical trial and received FURESTEM-AD Inj * Those who understand and voluntarily sign an informed consent form Exclusion Criteria: * None

Primary outcome measure(s)

  • Safety Assessment — 5 years follow-up after treatment
    Rate and Number of AESI(Adverse Event of Special Interest) and SS(Special Situation)

Trial sites (1)

FacilityCityRegionStatus
Bucheon Hospital, Soonchunhyang University Bucheon-si South Korea

More Kang Stem Biotech Co., Ltd. trials in South Korea

Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj Starting soon
A Multicenter, Open-Label, Single-Arm Extension Study to Evaluate the Safety and Efficacy of FURESTEM-OA-Kit Inj. in Knee Osteoarthritis Patients Who Received Placebo in the K0701 Phase 2a Trial Recruiting

Other trials for the same condition

A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07582237 on ClinicalTrials.gov ↗ ← All trials in South Korea